Introduction
============

Tuberculosis (TB) is an important global problem, especially multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). In 2015, the world-wide estimation of MDR-TB cases and deaths was 80,000 and 250,000, respectively.[@b1-idr-10-167] MDR-TB is caused by *Mycobacterium tuberculosis* (MTB), which resists at least 2 drugs (isoniazid \[INH\] and rifampicin \[RIF\]). Pre-XDR-TB is a disease caused by the *M. tuberculosis* strain, which resists INH and RIF and either a fluoroquinolone or a second-line injectable drug, but not both.[@b1-idr-10-167] XDR-TB is defined as MDR-TB, which adds more resistance to any fluoroquinolone and at least 1 of 3 injectable second-line drugs (amikacin, capreomycin, and kanamycin \[KAN\]).[@b2-idr-10-167] Approximately 9.5% of MDR-TB patients developed XDR-TB.[@b1-idr-10-167] Unfortunately, about 20% of MDR-TB cases were undetectable.[@b1-idr-10-167] Thailand is among the countries with a TB burden, as it was ranked within the top 20 countries with TB in 2015.[@b1-idr-10-167]

Early and accurate detection of M/XDR-TB is important for effectively treating and preventing its transmission.[@b3-idr-10-167]--[@b6-idr-10-167] However, the phenotypic drug susceptibility test (DST) takes weeks or months for culturing MTB and identifying the resisted drugs and requires a high level of microbiological safety.[@b7-idr-10-167],[@b8-idr-10-167] Diagnosis and treatment delays are among the major causes of the spread of the disease, which interferes with the TB control programs. A rapid molecular TB-DST test greatly increases the efficacy of MDR-TB treatment[@b5-idr-10-167],[@b6-idr-10-167],[@b9-idr-10-167] as the minimal turnaround time is \<1 day.[@b10-idr-10-167],[@b11-idr-10-167]

As the distribution of mutation in drug-resistant genes is region specific, knowing the epidemiology of the genetic drug resistance of M/XDR-TB in certain areas would be beneficial for developing specific and rapid molecular tests,[@b8-idr-10-167],[@b12-idr-10-167] as well as treatment protocols,[@b13-idr-10-167] because the prevalence of such resistance differs in various populations.[@b14-idr-10-167]--[@b16-idr-10-167] Many studies have focused on genetic drug resistance in MTB. INH is the main drug used; it is an effective anti-TB drug and has been used till date.[@b2-idr-10-167],[@b11-idr-10-167] The mechanism of INH resistance in MTB is associated with the mutations of *katG*, *inhA*, and *ahpC*.[@b17-idr-10-167]--[@b19-idr-10-167] The *katG* mutation was found in high levels of INH resistance,[@b20-idr-10-167],[@b21-idr-10-167] and the *inhA* mutation was found at low levels or monoresistance to INH.[@b20-idr-10-167],[@b22-idr-10-167] RIF is combined with INH as the main anti-TB drug, and it is inferred with transcription by the DNA-dependent RNA polymerase by binding to the β-subunit hindering transcription organisms related to *rpoB* 531 mutation,[@b23-idr-10-167]--[@b25-idr-10-167] which destroys the organisms.[@b26-idr-10-167],[@b27-idr-10-167]

In this study, we examined the distribution of drug-resistant gene mutations, including *katG*, *inhA*, *ahpC*, and *rpoB*, in M/XDR-TB isolates in the northern Thai population. Then, we identified the best mutation test panels for INH and RIF resistance.

Materials and methods
=====================

Two hundred and sixty-one M/XDR-TB isolates first diagnosed with MDR-TB or XDR-TB from patients between January 2005 and June 2012 were retrieved from an archive of the Laboratory of the Office of Disease Prevention and Control Region 10 (DPC10). According to the World Health Organization (WHO) criteria, MDR isolates resisted at least INH and RIF; and XDR isolates resisted INH, RIF, ofloxacin (OFX), and KAN. DPC10 hosts a regional TB laboratory, covering 8 provinces in the north of Thailand, and the isolates were subcultured. Only 34 specimens (9.5%) were grown in 5 mL of 7H9 broth supplemented with PANTA in 6 weeks and 3% Ogawa within 8 weeks. The bacterial agents were further examined for phenotypic DST and DNA sequencing.

Phenotypic drug susceptibility test
-----------------------------------

Thirty-four growing M/XDR-TB isolates were tested for first- and second-line drug resistance (INH, RIF, OFX, and KAN) using the proportion method with Lowensentein Jensen (LJ) medium[@b28-idr-10-167] at DPC10 laboratory. The DOTS-plus DST was performed according to the WHO guidelines,[@b29-idr-10-167] and all suspected TB and MDR-TB patients were investigated using 3 methods: 3 direct acid-fast bacilli sputum smear examinations, a *Mycobacterium* culture, and first-line DST,[@b29-idr-10-167] during the first diagnosis. Additionally, at the same time, a molecular test was carried out in order to confirm *M. tuberculosis*. DST was determined using the indirect agar proportion method with INH, RIF, streptomycin, and ethambutol. If there was resistance to INH and/or RIF, a second-line anti-TB DST was performed with OFX and KAN. For our study, LJ medium was supplemented individually with anti-TB drugs. INH (0.2 μg/mL), RIF (40.0 μg/mL), OFX (2.0 μg/mL), and KAN (30 μg/mL) were repeated in order to confirm that the results were the same as the previous results; if the results were not the same then they were excluded from the study.

DNA extraction
--------------

Thirty-four M/XDR-TB isolates were cultured on solid media (LJ and OGAWA). Chromosomal DNA was extracted using the MolecuTech REBA MTB-MDR 2011 commercial kit. Briefly, 1 loop (0.2 μL diameter sterile inoculating loop) of the cultured bacteria was resuspended in 50 μL of DNA extraction solution. The solution was vortexed for 1 min, boiled for 10 min, and centrifuged (13,000 rpm) for 3 min at room temperature. Then, 5--10 μL of the supernatant was transferred to a microtube (cryovial tube). The purified DNA pellet was stored at 4°C.

Sequencing method
-----------------

The polymerase chain reaction (PCR) and DNA sequencing parts were carried out at Macrogen Laboratory, Seoul, Republic of Korea. Four genetic loci, *katG*, *inhA*, *ahpC* (INH), and *rpoB* (RIF), were amplified by PCR, as shown in [Table S1](#SD1-idr-10-167){ref-type="supplementary-material"}.[@b30-idr-10-167],[@b31-idr-10-167] The used primers are shown in [Table S1](#SD1-idr-10-167){ref-type="supplementary-material"}. The amplified products were purified with a multiscreen filter plate (Millipore Corp., Bedford, MA, USA).

Analysis
========

DNA sequencing analysis
-----------------------

The sequencing data obtained from the ABI3730XL DNA analyzer were investigated for the presence or absence of mutations by alignments with the corresponding nucleotide sequences of *M. tuberculosis* (H37RV) using the NCBI nucleotide blast program.

Data analysis
-------------

The phenotypic DST and genetic site mutation for the DST data sets were compiled using an Excel 2010 database. Statistical analysis was performed using STATA version 11.0. The resistant genes and genetic site mutations were presented according to frequency and percentage.

Results
=======

Among the 34 growing M/XDR-TB isolates, 24 (70.5%) MDR-TB, 9 (26.5%) Pre-XDR-TB, and 1 (3.0%) XDR-TB were identified. All of the isolates were resistant to both INH and RIF. The frequency and patterns of genetic loci mutation are demonstrated in [Tables 1](#t1-idr-10-167){ref-type="table"} and [2](#t2-idr-10-167){ref-type="table"}. [Table 3](#t3-idr-10-167){ref-type="table"} exhibits the raw data of genetic mutation in all 34 isolates. Mutations were found, including *katG* in 20 isolates (58.8%), *inhA* in 27 isolates (79.4%), *ahpC* in 13 isolates (38.2%), and *rpoB* in 28 isolates (82.3%). INH-resistant gene mutations were found in 32 isolates (94.1% sensitivity). RIF-resistant gene mutations were identified in 28 isolates (82.4% sensitivity).

One isolate revealed no mutation for the studied genetic loci (no. 18). Two isolates showed no mutation for *katG*, *inhA*, or *ahpC*. (no. 2 and 18). For the INH-resistant genes, a single-gene mutation was found in 10 isolates (29.4%), 2 for *katG*, 7 for *inhA*, and 1 for *ahpC*. Double mutation was found in 16 isolates (47.1%), 10 for *katG*/*inhA*, 4 for *ihnA*/*ahpC*, and 2 for *katG*/*ahpC*. Triple *katG*/*inhA*/*ahpC* mutation was seen in 6 isolates (17.6%). Regarding the RIF-resistant gene, no *rpoB* mutation was found in 6 isolates (no. 5, 8, 11, 15, 8, and 34).

The common mutated genetic loci found in M/XDR-TB were *katG* 315 (n=12, 35.3%), *inhA* 14 (n=11, 32.4%), *ihnA* 114 (n=11, 32.4%), *ihnA* 84 (n=9, 26.5%), *rpoB* 507 (n=9, 26.47%), and *rpoB* 508 (n=9, 26.47%).

Discussion
==========

The frequency and distribution of drug-resistant mutations are variable across regions and countries ([Table 4](#t4-idr-10-167){ref-type="table"}). The frequency of *katG* mutation ranged from 58.5% to 93.7%,[@b39-idr-10-167] and the most commonly mutated *katG* locus was *katG* 315.[@b32-idr-10-167]--[@b37-idr-10-167],[@b39-idr-10-167],[@b40-idr-10-167] The reported frequency of *inhA* mutation was 4.7%--79.4%,[@b32-idr-10-167],[@b33-idr-10-167] and the most commonly mutated *inhA* locus was *inhA* 15.[@b32-idr-10-167]--[@b40-idr-10-167] The frequency of *ahpC* mutation was relatively low (9.1%--38.2%)[@b34-idr-10-167],[@b35-idr-10-167] and was extremely variable. The frequency of *rpoB* mutation was relatively high (80.8%--97.0%),[@b33-idr-10-167],[@b34-idr-10-167],[@b39-idr-10-167] predominantly at the locus *rpoB* 531.

Genomic tests or multiple genetic loci tests are not suitable for resource-limited countries. Developing test panels for M/XDR-TB drug-resistant genes would be more cost-effective if the test panels of the selected genetic loci provide high sensitivity and specificity. However, as the distributions of the gene mutations across the regions varied, a deeper analysis should be considered in further studies. The distribution of mutation patterns should be examined in each geographical areas before routine diagnostic services being implemented. According to the results of this study, we selected 8 INH-resistant gene mutation loci (*katG* 310, *katG* 340, *katG* 343, *inhA* 14, *inhA* 84, *inhA* 86, *inhA* 114, and *ahpC* 75) and 6 RIF-resistant gene mutation loci (*rpoB* 445, *rpoB* 450, *rpoB* 464, *rpoB* 490, *rpoB* 507, and *rpoB* 508) as the best panels for genetic drug resistance tests. Both the panels were able to detect all isolates with at least 1 mutation site for any *katG*/*inhA*/*ahpC* mutation and *rpoB* mutation. The sensitivities of the proposed INH resistance mutation test was 94.1% (32/34), while that of the RIF resistance mutation test was 82.4% (28/34).

Limitations
===========

The limitations of this study were the small sample size and the retrospective design. Only 34 isolates were available from a total of 261 isolates. Another weak point was that there was no control group, such as non-M/XDR-TB isolates.

Conclusion
==========

The results of this study confirm the presence of genetic drug-resistant mutations in the M/XDR-TB isolates in upper northern Thailand. We showed that our mutation patterns were different from other parts of Thailand and other countries. The distribution of these mutations in certain populations must be studied before developing specific mutation test panels for each area. These data and proposed mutation panels can be applied for further molecular M/XDR-TB diagnosis in the upper northern region of Thailand.

Supplementary material
======================

###### 

Primers used for sequencing

  -----------------------------------------------------------------------------------------------------------------------------------
  Gene     Primer    Nucleotide sequencing (5′--3′)   Product size (pb)   Temperature (°C)               Reference
  -------- --------- -------------------------------- ------------------- ------------------------------ ----------------------------
  *katG*   MtkatGf   ACCCGAGGCTGCTCCGCTGG             168                 94°C -- 20 s\                  Afanas'ev[@b41-idr-10-167]
                                                                          50°C -- 20 s 70 cycles\        
                                                                          72°C -- 20 s                   

           MtkatGr   CAGCTCCCACTCGTAGCCGT                                                                

  *inhA*   MtfabGf   GCCTCGCTGGCCCAGAAAGG             320                 94°C -- 20 s\                  Afanas'ev[@b41-idr-10-167]
                                                                          56°C -- 20 s 70 cycles\        
                                                                          72°C -- 20 s                   

           MtfabGr   CTCCGGATCCACGGTGGGT                                                                 

  *ahpC*   ahpC1 F   GCCTGGGTGTTCGTCACTGGT            359                 95°C -- 40 s 15 min (start)\   Valvatne[@b42-idr-10-167]
                                                                          94°C -- 40 s 30 cycles\        
                                                                          57°C -- 40 s 1 min\            
                                                                          72°C -- 40 s 15 min (final)    

           ahpC2 R   CGCAACGTCGACTGGCTCATA                                                               

  *rpoB*   MtrpoBf   GAGGCGATCACCGCAGAC               321                 94°C -- 20 s\                  Afanas'ev[@b41-idr-10-167]
                                                                          59°C -- 20 s 70 cycles\        
                                                                          72°C -- 20 s                   

           MtrpoBr   GGTACGGCGTTTCGATGAAC                                                                
  -----------------------------------------------------------------------------------------------------------------------------------
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###### 

Frequency of genetic site mutations of *katG*, *inhA*, *ahpC*, and *rpoB* genes in 34 M/XDR-TB isolates

  *katG*       n (%)       *inhA*       n (%)       *ahpC*      n (%)      *rpoB*       n (%)
  ------------ ----------- ------------ ----------- ----------- ---------- ------------ ----------
  *katG* 229   1 (2.9)     *inhA* 14    11 (32.4)   *ahpC* 10   4 (11.8)   *rpoB* 445   8 (23.5)
  *katG* 300   1 (2.9)     *inhA* 25    1 (2.9)     *ahpC* 12   4 (11.8)   *rpoB* 450   6 (17.7)
  *katG* 302   1 (2.9)     *inhA* 78    8 (23.5)    *ahpC* 20   4 (11.8)   *rpoB* 464   6 (17.7)
  *katG* 308   3 (8.8)     *inhA* 81    7 (20.6)    *ahpC* 22   3 (8.8)    *rpoB* 483   4 (11.8)
  *katG* 310   3 (8.8)     *inhA* 84    9 (26.5)    *ahpC* 75   7 (20.6)   *rpoB* 490   7 (20.6)
  *katG* 312   4 (11.8)    *inhA* 86    8 (23.5)    *ahpC* 76   6 (17.7)   *rpoB* 493   4 (11.8)
  *katG* 314   1 (2.9)     *inhA* 94    3 (8.8)                            *rpoB* 507   9 (26.5)
  *katG* 315   12 (35.3)   *inhA* 114   11 (32.4)                          *rpoB* 508   9 (26.5)
  *katG* 320   1 (2.9)                                                                  
  *katG* 340   4 (11.8)                                                                 
  *katG* 343   7 (20.6)                                                                 

**Abbreviation:** M/XDR-TB, multidrug/extensively drug-resistant tuberculosis.

###### 

Distribution of *Mycobacterium tuberculosis* genetic mutations with isoniazid and rifampicin resistance

  Gene mutation codon                                               n    \%
  ----------------------------------------------------------------- ---- ------
  *katG*                                                                 
   No mutation                                                      14   41.3
   *katG* 315                                                       9    26.7
   *katG* 320                                                       1    2.9
   *katG* 312                                                       1    2.9
   *katG* 343                                                       1    2.9
   *katG* 315 and *katG* 343                                        1    2.9
   *katG* 308 and *katG* 310                                        1    2.9
   *katG* 312 and *katG* 343                                        2    5.9
   *katG* 308, *katG* 315, and *katG* 340                           1    2.9
   *katG* 315, *katG* 340, and *katG* 343                           1    2.9
   *katG* 310, *katG* 314, *katG* 340, and *katG* 343               1    2.9
   *katG* 299, *katG* 300, *katG* 302, *katG* 310, and *katG* 312   1    2.9
  *InhA*                                                                 
   No mutation                                                      7    20.6
   *inhA* 14                                                        6    17.7
   *inhA* 25                                                        1    2.9
   *inhA* 86                                                        1    2.9
   *inhA* 114                                                       5    14.8
   *inhA* 14 and *inhA* 114                                         4    11.8
   *inhA* 84 and *inhA* 114                                         1    2.9
   *inhA* 78, *inhA* 81, and *inhA* 84                              1    2.9
   *inhA* 78, *inhA* 81, and *inhA* 86                              1    2.9
   *inhA* 78, *inhA* 84, and *inhA* 86                              1    2.9
   *inhA* 14, *inhA* 78, *inhA* 81, and *inhA* 84                   1    2.9
   *inhA* 78, *inhA* 81, *inhA* 84, and *inhA* 86                   1    2.9
   *inhA* 78, *inhA* 84, *inhA* 86, and *inhA* 114                  1    2.9
  * *inhA 81, *inhA* 84, *inhA* 86, and *inhA* 94                   1    2.9
   *inhA* 78, *inhA* 81, *inhA* 84, *inhA* 86, and *inhA* 94        2    5.9
  *ahpC*                                                                 
   No mutation                                                      21   61.8
   *ahpC* 10                                                        1    2.9
   *ahpC* 75                                                        1    2.9
   *ahpC* 10 and *ahpC* 12                                          1    2.9
   *ahpC* 12 and *ahpC* 20                                          1    2.9
   *ahpC* 75 and *ahpC* 76                                          6    17.7
   *ahpC* 10, *ahpC* 20, and *ahpC* 22                              1    2.9
   *ahpC* 12, *ahpC* 20, and *ahpC* 22                              1    2.9
   *ahpC* 10, *ahpC* 12, *ahpC* 20, and *ahpC* 22                   1    2.9
  *rpoB*                                                                 
   No mutation                                                      6    17.7
   *rpoB* 445                                                       2    5.9
   *rpoB* 508                                                       1    2.9
   *rpoB* 464                                                       2    5.9
   *rpoB* 450                                                       3    8.8
   *rpoB* 490                                                       2    5.9
   *rpoB* 507                                                       3    8.8
   *rpoB* 445 and *rpoB* 508                                        1    2.9
   *rpoB* 507 and *rpoB* 508                                        6    17.7
   *rpoB* 445 and *rpoB* 483                                        1    2.9
   *rpoB* 464 and *rpoB* 483                                        1    2.9
   *rpoB* 445, *rpoB* 464, and *rpoB* 504                           1    2.9
   *rpoB* 445, *rpoB* 490, and *rpoB* 493                           1    2.9
   *rpoB* 450, *rpoB* 490, and *rpoB* 493                           1    2.9
   *rpoB* 445, *rpoB* 464, *rpoB* 490, and *rpoB* 493               1    2.9
   *rpoB* 450, *rpoB* 490, *rpoB* 483, and *rpoB* 493               1    2.9
   *rpoB* 445, *rpoB* 464, *rpoB* 490, *rpoB* 483, and *rpoB* 493   1    2.9

###### 

Raw distribution of genetic site mutations of *katG*, *inhA*, *ahpC*, and *rpoB* genes in M/XDR-TB isolates

  No.   *katG* 299   *katG* 300   *katG* 302   *katG* 308   *katG* 310   *katG* 312   *katG* 314   *katG* 315   *katG* 320   *katG* 340   *katG* 343   *inhA* 14   *inhA* 25   *inhA* 78   *inhA* 81   *inhA* 84   i*nhA* 86   *inhA* 94   i*nhA* 114   *ahpC* 10   *ahpC* 12   *ahpC* 20   *ahpC* 22   *ahpC* 75   *ahpC* 76   *rpoB* 445   *rpoB* 450   *rpoB* 464   *rpoB* 483   *rpoB* 490   *rpoB* 493   *rpoB* 507   *rpoB* 508
  ----- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ----------- ----------- ----------- ----------- ----------- ----------- ----------- ------------ ----------- ----------- ----------- ----------- ----------- ----------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------
  1     Y            Y            Y            Y            Y            Y            --           --           --           --           --           --          --          --          --          --          --          --          --           --          --          --          --          --          --          Y            --           --           --           --           --           --           Y
  2     --           --           --           --           --           --           --           --           --           --           --           --          --          --          --          --          --          --          --           --          --          --          --          --          --          Y            --           Y            --           --           --           --           Y
  3     --           --           --           --           --           --           --           --           --           --           Y            --          Y           --          --          --          --          --          --           Y           --          --          --          --          --          --           --           --           --           Y            --           --           --
  4     --           --           --           --           --           Y            --           --           --           --           Y            --          --          --          --          Y           --          --          Y            --          --          --          --          --          --          --           --           --           --           --           --           Y            Y
  5     --           --           --           Y            Y            --           --           --           --           --           --           --          --          --          --          --          --          --          --           --          --          --          --          --          --          --           --           --           --           --           --           --           --
  6     --           --           --           --           --           --           --           Y            --           --           --           Y           --          --          --          --          --          --          Y            --          --          --          --          --          --          Y            --           --           Y            --           --           --           --
  7     --           --           --           --           --           --           --           Y            --           Y            Y            Y           --          --          --          --          --          --          Y            --          Y           Y           Y           --          --          Y            --           Y            Y            Y            Y            --           --
  8     --           --           --           --           --           --           --           --           --           --           --           Y           --          --          --          --          --          --          Y            Y           Y           Y           Y           --          --          --           --           --           --           --           --           --           --
  9     --           --           --           --           --           --           --           Y            --           --           Y            Y           --          --          --          --          --          --          --           --          --          --          --          --          --          --           Y            --           --           Y            Y            --           --
  10    --           --           --           --           --           Y            --           --           --           --           Y            --          --          Y           Y           Y           Y           --          --           --          --          --          --          --          --          Y            --           --           --           Y            Y            --           --
  11    --           --           --           --           --           --           --           --           --           --           --           --          --          --          --          --          --          --          --           --          --          --          --          Y           Y           --           --           --           --           --           --           --           --
  12    --           --           --           Y            --           --           --           Y            --           Y            --           Y           --          --          --          --          --          --          --           Y           --          Y           Y           --          --          --           --           --           --           --           --           Y            Y
  13    --           --           --           --           --           --           --           --           --           --           --           --          --          --          --          --          --          --          Y            --          --          --          --          --          --          --           --           --           --           --           --           Y            --
  14    --           --           --           --           --           --           --           Y            --           --           --           --          --          --          --          --          --          --          Y            Y           Y           --          --          --          --          Y            --           --           --           --           --           --           --
  15    --           --           --           --           --           --           --           --           --           --           --           Y           --          --          --          --          --          --          --           --          --          --          --          Y           Y           --           --           --           --           --           --           --           --
  16    --           --           --           --           --           --           --           --           --           --           --           --          --          --          --          --          Y           --          --           --          --          --          --          --          --          --           --           --           --           Y            --           --           --
  17    --           --           --           --           --           Y            --           --           --           Y            Y            --          --          Y           --          Y           Y           --          Y            --          --          --          --          --          --          --           Y            --           Y            Y            Y            --           --
  18    --           --           --           --           --           --           --           --           --           --           --           --          --          --          --          --          --          --          --           --          --          --          --          --          --          --           --           --           --           --           --           --           --
  19    --           --           --           --           --           --           --           --           --           --           --           Y           --          --          --          --          --          --          --           --          --          --          --          --          --          --           Y            --           --           --           --           --           --
  20    --           --           --           --           --           --           --           --           --           --           --           --          --          Y           --          Y           Y           --          --           --          --          --          --          Y           --          Y            Y            Y            --           Y            --           --           --
  21    --           --           --           --           --           --           --           --           --           --           --           Y           --          Y           Y           Y           --          --          --           --          --          --          --          --          --          Y            --           --           --           --           --           --           --
  22    --           --           --           --           --           --           --           Y            --           --           --           --          --          --          --          --          --          --          Y            --          --          --          --          --          --          --           Y            --           --           --           --           --           --
  23    --           --           --           --           Y            --           Y            --           --           Y            Y            --          --          Y           Y           Y           Y           Y           --           --          Y           Y           --          --          --          --           Y            --           --           --           --           --           --
  24    --           --           --           --           --           --           --           Y            --           --           --           --          --          Y           Y           --          Y           --          --           --          --          --          --          --          --          --           --           --           --           --           --           Y            Y
  25    --           --           --           --           --           --           --           Y            --           --           --           Y           --          --          --          --          --          --          --           --          --          --          --          --          --          --           --           --           --           --           --           --           Y
  26    --           --           --           --           --           --           --           --           --           --           --           Y           --          --          --          --          --          --          --           --          --          --          --          --          --          --           --           --           --           --           --           Y            Y
  27    --           --           --           --           --           --           --           --           --           --           --           Y           --          --          --          --          --          --          Y            --          --          --          --          --          --          --           --           --           --           --           --           Y            Y
  28    --           --           --           --           --           --           --           Y            --           --           --           --          --          Y           Y           Y           Y           Y           --           --          --          --          --          --          --          --           --           --           --           --           --           Y            Y
  29    --           --           --           --           --           --           --           --           --           --           --           --          --          Y           Y           Y           --          --          --           --          --          --          --          --          --          --           --           Y            Y            --           --           --           --
  30    --           --           --           --           --           --           --           --           Y            --           --           --          --          --          Y           Y           Y           Y           --           --          --          --          --          --          --          --           --           Y            --           --           --           --           --
  31    --           --           --           --           --           --           --           Y            --           --           --           --          --          --          --          --          --          --          --           --          --          --          --          Y           Y           --           --           Y            --           --           --           --           --
  32    --           --           --           --           --           --           --           Y            --           --           --           --          --          --          --          --          --          --          --           --          --          --          --          Y           Y           --           --           --           --           --           --           Y            --
  33    --           --           --           --           --           --           --           --           --           --           --           --          --          --          --          --          --          --          Y            --          --          --          --          Y           Y           --           --           --           --           --           --           Y            --
  34    --           --           --           --           --           --           --           Y            --           --           --           --          --          --          --          --          --          --          Y            --          --          --          --          Y           Y           --           --           --           --           --           --           --           --

**Notes:** -, no mutation; Y, presence of mutation; gray column, proposed mutation test panels.

**Abbreviation:** M/XDR-TB, multidrug/extensively drug-resistant tuberculosis.

###### 

Distribution of genetic mutation for isoniazid and rifampicin resistance

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Countries                                                       *katG* (n %), top 3 common loci   *inhA* (n %), top 3 common loci   *ahpC* (n %), top 3 common loci   *rpoB* (n %), top 3 common loci
  --------------------------------------------------------------- --------------------------------- --------------------------------- --------------------------------- ---------------------------------
  Thailand (the present study) in the north of Thailand           20/34 (58.8%)\                    27/34 (79.4%)\                    13/34 (38.2%)\                    28/34 (82.3%)\
                                                                  315, 343, 312, 340                14, 114, 84                       75, 76, 10, 12, 20                507, 508, 445

  Thailand[@b32-idr-10-167] (in the middle of Thailand in 2007)   25/29 (86.21%)\                   7/25 (24.0%)\                     NA                                NA
                                                                  315, 463, 308                     (−15), (−8), 21                                                     

  Myanmar[@b33-idr-10-167]                                        31/33 (72.1%)\                    2/33 (4.7%)\                      NA                                32/33 (97.0%)\
                                                                  315                               (−15)                                                               531, 526, 516

  People's Republic of China[@b34-idr-10-167]                     178/242 (73.9%)\                  26/242 (10.7%)\                   22/242 (9.1%)\                    213/242 (88.0%)\
                                                                  315, 295, 299                     (15), (−8), 25                    (−10), (−6), (−12)                531, 526, 516

  Poland[@b35-idr-10-167]                                         40/50 (80%)\                      8/50 (16%)\                       5/50 (10%)\                       NA
                                                                  315, 463, 234                     (−15), (−8), 289                  48, 54, 57                        

  Switzerland[@b36-idr-10-167]                                    101/154 (65.6%)\                  35/154 (22.7%)\                   NA                                NA
                                                                  315                               (−15)                                                               

  Argentina[@b37-idr-10-167]                                      43/71 (60.5%)\                    16/71 (22.5%)\                    NA                                NA
                                                                  315                               (−15)                                                               

  South Africa[@b38-idr-10-167]                                   NA                                165/232 (71%)\                    NA                                NA
                                                                                                    (−15), (−8)                                                         

  Morocco[@b39-idr-10-167]                                        15/16 (93.7%)\                    1/16 (6.2%)\                      NA                                21/26 (80.8%)\
                                                                  315                               (−15)                                                               531, 316, 513, 526

  India, Moldova, Philippines, and\                               268/316 (84.8%)\                  101/316 (32.0%)\                  NA                                NA
  South Africa[@b40-idr-10-167]                                   315                               (−15), (−8), (−17)                                                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviation:** NA, not available.
